Carolyn's and Marc's 40th Birthday Party Co-authors. Deepak L. Bhatt, MD, MPH, MBADr. Valentin Fuster Professor of Cardiovascular Medicine, Icahn School of Medicine at Marc Bonaca MD MPH - Google Scholar
VOYAGER, Atherosclerotic Disease, and More: An Interview with Marc Bonaca, MD Dr Marc P Bonaca (University of Colorado School of Medicine, Aurora, CO, US) shares the primary results of the Voyager Pad
Patients with PAD, prior MI benefit greatly from long-term ticagrelor therapy Chloe Wilson and Flavia Geraldes of The Lancet caught up with Professor Marc Bonaca and Professor Subodh Verma at ACC
Marc P. Bonaca, MD of the TIMI Study Group, discusses a new approach for assessing risk in patients with stable ischemic HD. Dr Marc P. Bonaca is a cardiologist and vascular medicine specialist serving as Executive Director of the Colorado Prevention Center (CPC) and Director of New Trials, New Therapies, and Some Old Challenges: An Interview with Marc Bonaca, MD
Marc P. Bonaca, MD, MPH, FACC, FAHA • CPC Clinical Research Late-Breaker host, Dr Harriette Van Spall (McMaster University, Hamilton, CA) is joined by Dr Marc Bonaca (University of In this clip from VIVA's recent Data Deep Dive, Dr. Marc Bonaca presents new findings from the STRIDE-PAD study, leading to a
Dr. Marc P. Bonaca, MD, MPH, is a Cardiologist and Vascular Medicine Specialist who serves as the Executive Director of CPC Clinical Research and CPC Community January 25th, 2014 at Legal Seafood Harborside Roofdeck. TRA 2°P-TIMI 50 Trial: New Stroke and Outcomes with Vorapaxar
Title: Improving Outcomes in Peripheral Artery Disease: Stepping in the Right Direction Presenter: Marc P. Bonaca, MD, MPH, Vorapaxar reduces peripheral revascularization in patients with PAD. In this interview, Marc Bonaca, MD, of the TIMI Study Group,
Dr. Valentin Fuster talks with experts about the practice-changing elements from the VICTORIA and VOYAGER PAD trials. Dr. Marc Bonaca and Dr. Shiavax Rao on Primary Results of the STRIDE Trial
Dr. Marc Bonaca is a Cardiologist and Vascular Medicine Specialist who serves as the Executive Director of CPC Clinical Research and CPC Community Health. In the second part of this two-part interview, Marc Bonaca, MD, a professor of medicine and Director of Vascular Research at the Prof Marc p Bonaca on THEMIS-PAD
For the first time in over TWO DECADES, there's a new medication treatment approach for peripheral artery disease! Marc Bonaca, MD. Professor, Medicine-Cardiology. Faculty Photo. Medical DR, Garcia LA, Kum SWC, Rundback J, Armstrong E, Lee JK, Khatib Y, Weinberg Date: February 16, 2021 Presenters: Geoffrey Barnes, MD, MSc, Marc Bonaca, MD, MPH, Henry Han, MD, Eva Kline-Rogers, MS,
For more details you can visit our facebook page : facebook: or call our helpline VESS Winter Annual Meeting (Virtual) - Session 2, Talk 2 ACC.20/WCC Virtual: Day 1 Cardiology Hour
How would you know if you had leg clots? || Dr Rajiv Parakh || Healthy Blood Vessels. Marc Bonaca - CPC Clinical Research | LinkedIn
VOYAGER-PAD helps to underscore that peripheral artery disease is a different disease state than coronary disease and different VOYAGER PAD | Marc Bonaca, MD, MPH
Marc Bonaca MD. Professor. Cardiology (SOM). Email Address:marc.bonaca@cuanschutz.edu Find a Doctor · Clinical Trials. Partnerships. UCHealth University of AHA 22: BT001 PIVOTAL: nCBT in Pts with Type II Diabetes | Dr Marc Bonaca Marc P. Bonaca, MD, a professor of medicine and Director of Vascular Research at the University of Colorado, talks with DocWire
Visit Radcliffe Cardiology: Emerging Role of Rivaroxaban Across the Atherothrombotic Disease Spectrum Walking as PAD Therapy Breakthrough Research of the Year | Global PAD Impact Awards
Struggling to walk as far as you used to? It might not be aging—it could be Peripheral Artery Disease (PAD), a dangerous Marc P. Bonaca, MD, of the TIMI Study Group at Brigham and Women's Hospital in Boston, talks with CSWN about the results of
Data Deep Dive: SOUL Study Discussion Data Deep Dive: The Latest Insights from STRIDE-PAD and SOUL ACC 25 Late-Breaking Discussion: STRIDE: Semaglutide for Functional Capacity in Pts with T2D and PAD
STICH was an important trial presented at the American College of Cardiology 2011 Scientific Session. Listen to primary results Marc P Bonaca, Cardiology | Radcliffe Cardiology marc.bonaca@cuanschutz.edu
Catheter Techniques Marc Bonaca, MD.
Clot Chronicles: PAD Management-Key Insights from the VOYAGER PAD Trial ACC 2020: Primary Results Of The Voyager Pad Trial — Dr Marc P Bonaca Breakthrough Leg Cramp Drug For PAD Patients With Diabetes
ACC 2019: DECLARE TIMI 58 - Dr Marc P. Bonaca Novel Antithrombotics and Antiplatelets in the Treatment of PAD
Marc Bonaca MD MPH (@MarcBonaca) / Posts / X A TIMI Risk Score for Stable Ischemic Heart Disease? Dr. Marc Bonaca, Associate Physician, Brigham & Women's Hospital 2.3.16.
Latest P2Y12 Inhibition Research from #ACC18 Marc Bonaca MD - Peripheral Artery Disease New Data and New Guidelines ESC 2016 Dr Marc Bonaca Interview
Dr. Marc Bonaca and I discussed the STRIDE trial. Semaglutide improves functional outcomes in DM pts with symptomatic PAD, addressing a critical unmet need. Marc Peter Bonaca, MD, MPH, talks about Acute Aortic Syndrome and the importance of diagnosing and treating rapidly, as BWH
Stephen Crowley, M.D. discusses when Cardiologists use catheter techniques. To find out more information please visit our Cleerly's new Cardiac Beat video series features conversations on the future of wholeheart™ care. In our first Cardiac Beat, Marc Bonaca, MD | Profiles | School of Medicine | University of
FITsOnTheGo is an initiative led by the Mayo Clinic Rochester Cardiology Fellowship in collaboration with the ACC. Each year Rivaroxaban for Reducing Vascular Event Risks after Limb Revascularization for Peripheral Artery In this new paper in JACC, Marc P. Bonaca, MD, of the TIMI Study Group, discusses new data from PEGASUS-TIMI 54. The CSWN
Grand Rounds 3/31/2021 The STRIDE Trial: A New Dawn for Patients Living with PAD and Diabetes I've spent years telling the stories of peripheral artery
Dr Marc Bonaca Discusses the Significance of VOYAGER-PAD Trial Findings in Cardiology Trouble Walking? Take Off Your Socks At the Doc! #shorts #viral
Why Your Walking Problems Could Be Poor Circulation Called PAD Vorapaxar and Peripheral Revascularization: More Than Purely Anti-Thrombotic Effects? AHA 2015 | PEGASUS-TIMI 54 Trial
Marc P. Bonaca, MD, of Brigham and Women's Hospital and a member of the TIMI Study Group, talks with CSWN about stroke and Marc Bonaca's profile on LinkedIn, a professional community of 1 billion members Marc Bonaca. CPC Clinical Research Brigham and Women's Hospital. Denver ACC/AHA Aortic Disease Guidelines | AHA 2022
Ticagrelor reduces risk of limb events in patients with CAD and T2D; Greater benefit in PAD. Acute Aortic Syndrome Video - Brigham and Women's Hospital
Marc Bonaca MD MPH Cardiology and Vascular Medicine Specialist. Executive Director of CPC Clinical Research. Director of Vascular Research. University of TRA2P TIMI 50 Trial in PAD by Dr. Marc Bonaca from Brigham and Women's Hospital, Boston, MA
Late-breaking data from the STRIDE and SOUL studies show semaglutide improved symptoms, walking distance, and quality of Marc Bonaca discusses the aims and key findings of the PEGASUS-TIMI 54 trial, and how they could be incorporated into clinical
Marc Bonaca & Subodh Verma on the STRIDE trial #acc25 #cardiology Antithrombotic Therapy for Long-Term Secondary PreventionClinical Challenges In today's podcast we are joined by Dr. Marc Bonaca to discuss the findings of the recent VOYAGER PAD trial and the use of
The Global PAD Association is thrilled to announce Dr. Marc Bonaca and his research team as recipients of the "Walking As Dr. Bonaca, the Principal Investigator of VOYAGER PAD, revisits key findings from the trial and discusses implications for your TRA 2°P-TIMI 50 Trial: Vorapaxar and Stent Thrombosis
VIVA Explores VOYAGER Findings The Cardiac Beat: Cleerly Care Pathway Marc Petter Bonaca, MD, MPH & Investigator in the TIMI Study Group discusses efficacy and safety of ticagrelor as long-term
Dr Marc P Bonaca (University of Colorado, Aurora, CO, US) discusses the results of the THEMIS trial focusing on the Dr. Marc Bonaca and I discussed the STRIDE trial. Semaglutide
PAD Treatment Breakthrough: Diabetes and Weight Loss Drug Reduces leg Pain Join Dr. Marc Bonaca, renowned Interventional Cardiologist and Chairman of the American Heart Association PAD Collaborative,
Marc Bonaca MD specializes in Cardiology at UCHealth Heart and Vascular Center - Anschutz Medical Campus. The American College of Cardiology Scientific Sessions in Orlando, Florida, is full of new research. One of the worlds experts on
Controversy in Vascular Care: STRIDE-PAD Findings Spark Heated Panel Debate Interview: Developments in Atherosclerotic Disease Treatment, COVID-19, and More
Marc P. Bonaca, MD, Professor of Medicine and Director of Vascular Research at the University of Colorado, provides some STICH Trial Analysis
Peripheral Artery Disease and Dual Inhibition Therapy: Vascular Protection in Patients with CAD/PAD Dr. Marc Bonaca on the VOYAGER PAD Study Ticagrelor as Long-Term Secondary Prevention in Patients with PAD and Prior MI
ESC 2020: The THEMIS-PAD Trial — Dr Marc P Bonaca Speakers: Drs. C. Michael Gibson and Marc Bonaca Drs. C. Michael Gibson and Marc Bonaca discuss updates and key
Marc P. Bonaca, MD, MPH | Cardiometabolic Health Congress In this clip from VIVA's recent Data Deep Dive, Dr. Darren McGuire presents new findings from the SOUL study. Moderator: Joshua Study PI Dr. Marc Bonaca presents VOYAGER results to VIVA board members in this roundtable conversation.
Investigator Marc Bonaca, MD, MPH reports the results of the VOYAGER PAD trial, which examined reducing the risk of adverse Marc Bonaca MD | Cardiology | UCHealth Dr Marc P. Bonaca (University of Colorado School of Medicine, Aurora, Colorado, US) discusses DECLARE - TIMI 58
Peter Block, MD, FACC, interviews Marc P. Bonaca, MD. Title: Racial and regional disparities in the utilization of preventative care strategies among patients with peripheral artery disease